nach oben

Hepatology International

Erschienen in:

22.06.2017 | Review Article

Current progress in host innate and adaptive immunity against hepatitis C virus infection

verfasst von: Jijing Shi, Yuanyuan Li, Wenxian Chang, Xuexiu Zhang, Fu-Sheng Wang

Erschienen in: Hepatology International | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Hepatitis C virus (HCV) infects more than 170 million people worldwide and is the main cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. Although the newly developed direct-acting antivirals (DAAs) have transformed the treatment of HCV infection, controlling HCV infection on a global scale remains a challenge because of the high cost, low resistance barrier of DAAs and lack of HCV vaccine. The host immune responses associated with HCV infection, especially HCV-specific T cellular immunity, determine the outcome of HCV infection: either acute or chronic infection. It is important to fully interpret the immunopathogenesis of HCV infection and consequently to exploit effective strategies to eliminate HCV. Here, we review the current progress in HCV immunology, which will deepen our understanding of the spectrum of HCV infection and immunity in humans.

Webster DP, Klenerman P, Dusheiko GM. Hepatitis C. Lancet. 2015;385:1124–1135

Rehermann B. HCV in 2015: advances in hepatitis C research and treatment. Nat Rev Gastroenterol Hepatol 2016;13:70–72

Heathcote EJ. Prevention of hepatitis C virus-related hepatocellular carcinoma. Gastroenterology 2004;127:S294–S302

Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359–362

Khan AG, Whidby J, Miller MT, et al. Structure of the core ectodomain of the hepatitis C virus envelope glycoprotein 2. Nature 2014;509:381–384

Yang Z, Wang X, Chi X, et al. Neglected but important role of apolipoprotein E exchange in hepatitis C virus infection. J Virol 2016;90:9632–9643

Fauvelle C, Felmlee DJ, Crochet E, et al. Apolipoprotein E mediates evasion from hepatitis C virus neutralizing antibodies. Gastroenterology 2016;150:206–217

Hiet MS, Bauhofer O, Zayas M, et al. Control of temporal activation of hepatitis C virus-induced interferon response by domain 2 of nonstructural protein 5A. J Hepatol 2015;63:829–837

Shata MT, Anthony DD, Carlson NL, et al. Characterization of the immune response against hepatitis C infection in recovered, and chronically infected chimpanzees. J Viral Hepatol 2002;9(6):400–410

10.

Lechner F, Wong DK, Dunbar PR, et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000;191(9):1499–1512

11.

Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol 2016;16:509–523

12.

Lauer GM. Immune responses to hepatitis C virus (HCV) infection and the prospects for an effective HCV vaccine or immunotherapies. J Infect Dis 2013;207(Suppl 1):S7–S12

13.

Takaki A, Wiese M, Maertens G, et al. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C. Nat Med 2000;6(5):578–582

14.

Veerapu NS, Raghuraman S, Liang TJ, et al. Sporadic reappearance of minute amounts of hepatitis C virus RNA after successful therapy stimulates cellular immune responses. Gastroenterology 2011;140(2):676–685

15.

Penna A, Pilli M, Zerbini A, et al. Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology 2007;45(3):588–601

16.

Abdel-hakeem MS, Shoukry NH. Protective immunity against hepatitis C: many shades of gray. Front Immunol 2014;5:274

17.

Wiegand J, Jäckel E, Cornberg M, et al. Long-term follow-up after successful interferon therapy of acute hepatitis C. Hepatology 2004;40(1):98–107

18.

Zibert A, Meisel H, Kraas W, et al. Early antibody response against hypervariable region 1 is associated with acute self-limiting infections of hepatitis C virus. Hepatology 1997;25(5):1245–1249

19.

Swann RE, Mandalou P, Robinson MW, et al. Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection. J Viral Hepatol 2016;23:873–880

20.

Ahlenstiel G, Martin MP, Gao X, et al. Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses. J Clin Invest 2008;118:1017–1026

21.

Matsuura K, Tanaka Y. Host genetic variants influencing the clinical course of hepatitis C virus infection. J Med Virol 2016;88:185–195

22.

Wandrer F, Falk CS, John K, et al. Interferon-mediated cytokine induction determines sustained virus control in chronic hepatitis C virus infection. J Infect Dis 2016;213:746–754

23.

Lau DT, Negash A, Chen J, et al. Innate immune tolerance and the role of kupffer cells in differential responses to interferon therapy among patients with HCV genotype 1 infection. Gastroenterology 2013;144(2):402–413

24.

Miyagi T, Takehara T, Nishio K, et al. Altered interferon-alpha signaling in natural killer cells from patients with chronic hepatitis C virus infection. J Hepatol 2010;53:424–430

25.

Mondelli MU. Direct-acting antivirals cure innate immunity in chronic hepatitis C. Gastroenterology 2015;149:25–28

26.

Yin W, Tong S, Zhang Q, et al. Functional dichotomy of Vδ2 γδ T cells in chronic hepatitis C virus infections: role in cytotoxicity but not for IFN-γ production. Sci Rep 2016;6:26296

27.

Barathan M, Mohamed R, Vadivelu J, et al. Peripheral loss of CD8(+)CD161(++)TCRVα7.2(+) mucosal-associated invariant T cells in chronic hepatitis C virus-infected patients. Eur J Clin Invest 2016;46:170–180

28.

Zhang Y, El-Far M, Dupuy FP, et al. HCV RNA activates APCs via TLR7/TLR8 while virus selectively stimulates macrophages without inducing antiviral responses. Sci Rep 2016;6:29447

29.

Raghuraman S, Park H, Osburn WO, et al. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T cell exhaustion. J Infect Dis 2012;205:763–771

30.

Claassen MA, Janssen HL, Boonstra A. Role of T cell immunity in hepatitis C virus infections. Curr Opin Virol 2013;3(4):461–467

31.

Gupta PK, Godec J, Wolski D, et al. CD39 expression identifies terminally exhausted CD8⁺ T cells. PLoS Pathog 2015;11:e1005177

32.

Hartling HJ, Ballegaard VC, Nielsen NS, et al. Immune regulation in chronic hepatitis C virus infection. Scand J Gastroenterol 2016;51:1387–1397

33.

Radziewicz H, Ibegbu CC, Fernandez ML, et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J Virol 2007;81(6):2545–2553

34.

Burke Schinkel SC, Carrasco-Medina L, Cooper CL, et al. Generalized liver- and blood-derived CD8+ T-cell impairment in response to cytokines in chronic hepatitis C virus infection. PLoS One 2016;11:e0157055

35.

Bhattarai N, McLinden JH, Xiang J, et al. Conserved motifs within hepatitis C virus envelope (E2) RNA and protein independently inhibit T cell activation. PLoS Pathog 2015;11:e1005183

36.

Chen JH, Perry CJ, Tsui YC, et al. Prostaglandin E2 and programmed cell death 1 signaling coordinately impair CTL function and survival during chronic viral infection. Nat Med 2015;21:327–334

37.

Pelletier S, Bedard N, Said E, et al. Sustained hyperresponsiveness of dendritic cells is associated with spontaneous resolution of acute hepatitis C. J Virol 2013;87(12):6769–6781

38.

Zabaleta A, Riezu-Boj JI, Larrea E, et al. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance. J Med Virol 2016;88(5):843–851

39.

Liang CC, Liu CH, Lin YL, et al. Functional impairment of dendritic cells in patients infected with hepatitis C virus genotype 1 who failed peginterferon plus ribavirin therapy. J Med Virol 2011;83(7):1212–1220

40.

Rana D, Chawla YK, Duseja A, et al. Functional reconstitution of defective myeloid dendritic cells in chronic hepatitis C infection on successful antiviral treatment. Liver Int 2012;32(7):1128–1137

41.

Rodrigue-Gervais IG, Rigsby H, Jouan L, et al. Intact dendritic cell pathogen-recognition receptor functions associate with chronic hepatitis C treatment-induced viral clearance. PLoS One 2014;9(7):e102605

42.

Crosignani A, Riva A, Della BS. Analysis of peripheral blood dendritic cells as a non-invasive tool in the follow-up of patients with chronic hepatitis C. World J Gastroenterol 2016;22(4):1393–1404

43.

Tu Z, Zhang P, Li H, et al. Cross-linking of CD81 by HCV-E2 protein inhibits human intrahepatic plasmacytoid dendritic cells response to CpG-ODN. Cell Immunol 2013;284(1–2):98–103

44.

Sachdeva M, Chawla YK, Arora SK. Dendritic cells: the warriors upfront-turned defunct in chronic hepatitis C infection. World J Hepatol 2015;7(19):2202–2208

45.

Losikoff PT, Self AA, Gregory SH. Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence 2012;3(7):610–620

46.

Rodrigue-Gervais IG, Rigsby H, Jouan L, et al. Dendritic cell inhibition is connected to exhaustion of CD8+ T cell polyfunctionality during chronic hepatitis C virus infection. J Immunol 2010;184(6):3134–3144

47.

Ryan EJ, Stevenson NJ, Hegarty JE, et al. Chronic hepatitis C infection blocks the ability of dendritic cells to secrete IFN-alpha and stimulate T-cell proliferation. J Viral Hepatol 2011;18(12):840–851

48.

Zhao L, Tyrrell DL. Myeloid dendritic cells can kill T cells during chronic hepatitis C virus infection. Viral Immunol 2013;26(1):25–39

49.

Zeng QL, Yang B, Sun HQ, et al. Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR ζ chain expression on CD8⁺ T cells in chronic hepatitis C patients. Mol Cells 2014;37(1):66–73

50.

Ren JP, Zhao J, Dai J, et al. Hepatitis C virus-induced myeloid-derived suppressor cells regulate T cell differentiation and function via the STAT3 pathway. Immunology 2016;148:377–386

51.

Grakoui A, Shoukry NH, Woollard DJ, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003;302(5645):659–662

52.

Raziorrouh B, Ulsenheimer A, Schraut W, et al. Inhibitory molecules that regulate expansion and restoration of HCV-specific CD4+ T cells in patients with chronic infection. Gastroenterology 2011;141(4):1422–1431

53.

Kared H, Fabre T, Bedard N, et al. Galectin-9 and IL-21 mediate cross-regulation between Th17 and Treg cells during acute hepatitis C. PLoS Pathog 2013;9:e1003422

54.

Mele D, Mantovani S, Oliviero B, et al. Hepatitis C virus inhibits CD4 T cell function via binding to Toll-like receptor 7. Antiviral Res 2017;137:108–111

55.

Barnes E, Gelderblom HC, Humphreys I, et al. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J Infect Dis 2009;199(6):819–828

56.

Kanto T, Hayashi N. Immunopathogenesis of hepatitis C virus infection: multifaceted strategies subverting innate and adaptive immunity. Intern Med 2006;45:183–191

57.

Chang Q, Wang YK, Zhao Q, et al. Th17 cells are increased with severity of liver inflammation in patients with chronic hepatitis C. J Gastroenterol Hepatol 2012;27:273–278

58.

Neuman MG, Sha K, Esquerra R, et al. Inflammation and repair in viral hepatitis C. Dig Dis Sci 2008;53:1468–1487

59.

Pembroke T, Christian A, Jones E, et al. The paradox of NKp46+ natural killer cells: drivers of severe hepatitis C virus-induced pathology but in vivo resistance to interferon α treatment. Gut 2014;63(3):515–524

60.

Kang W, Shin EC. Clinical implications of chemokines in acute and chronic hepatitis C virus infection. Yonsei Med J 2011;52:871–878

61.

Szabo G, Petrasek J. Inflammasome activation and function in liver disease. Nat Rev Gastroenterol Hepatol 2015;12:387–400

62.

Ren JP, Ying RS, Cheng YQ, et al. HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development. J Viral Hepatol 2016;23:755–766

63.

Veerapu NS, Park SH, Tully DC, et al. Trace amounts of sporadically reappearing HCV RNA can cause infection. J Clin Invest 2014;124(8):3469–3478

64.

Dessouki O, Kamiya Y, Nagahama H, et al. Chronic hepatitis C viral infection reduces NK cell frequency and suppresses cytokine secretion: reversion by anti-viral treatment. Biochem Biophys Res Commun 2010;393(2):331–337

65.

Ahlenstiel G, Edlich B, Hogdal LJ, et al. Early changes in natural killer cell function indicate virologic response to interferon therapy for hepatitis C. Gastroenterology 2011;141(4):1231–1239

66.

Larrubia JR, Moreno-Cubero E, Miquel J, et al. Hepatitis C virus-specific cytotoxic T cell response restoration after treatment-induced hepatitis C virus control. World J Gastroenterol 2015;21:3480–3491

67.

Zhang C, Hua R, Cui Y, et al. Comprehensive mapping of antigen specific T cell responses in hepatitis C virus infected patients with or without spontaneous viral clearance. PLoS One 2017;12(2):e0171217

68.

Serti E, Chepa-Lotrea X, Kim YJ, et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 2015;149:190–200.e2

69.

Meissner EG, Wu D, Osinusi A, et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 2014;124:3352–3363

70.

Martin B, Hennecke N, Lohmann V, et al. Restoration of HCV-specific CD8⁺ T cell function by interferon-free therapy. J Hepatol 2014;61:538–543

71.

Burchill MA, Golden-Mason L, Wind-Rotolo M, et al. Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals. J Viral Hepatol 2015;22(12):983–991

72.

Hofmann M, Thimme R. MAIT be different-persisting dysfunction after DAA-mediated clearance of chronic hepatitis C virus infection. Eur J Immunol 2016;46(9):2099–2102

73.

Hengst J, Falk CS, Schlaphoff V, et al. DAA-induced HCV clearance does not completely restore the altered cytokine and chemokine milieu in patients with chronic hepatitis C. J Infect Dis 2016;214(12):1965–1974

74.

Callendret B, Eccleston HB, Satterfield W, et al. Persistent hepatitis C viral replication despite priming of functional CD8+ T cells by combined therapy with a vaccine and a direct-acting antiviral. Hepatology 2016;63:1442–1454

75.

Shrivastava S, Wilson E, Poonia B, et al. Augmentation of HCV specific immunity and sustained virological response (SVR). J Viral Hepatol 2017. doi:10.1111/jvh.12702

Titel: Current progress in host innate and adaptive immunity against hepatitis C virus infection
verfasst von: Jijing Shi
Yuanyuan Li
Wenxian Chang
Xuexiu Zhang
Fu-Sheng Wang
Publikationsdatum: 22.06.2017
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 4/2017
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-017-9805-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Current progress in host innate and adaptive immunity against hepatitis C virus infection

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2017

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Noninvasive serum models to predict significant liver related events in chronic hepatitis C

Safety, pharmacokinetics and pharmacogenetics of a single ascending dose of pradefovir, a novel liver-targeting, anti-hepatitis B virus drug, in healthy Chinese subjects

Extracorporeal devices for treatment of refractory pruritus in cholestatic liver disease

Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin